PAAM Hybrid 2023
BackLong-Term Dupilumab Treatment is Not Associated With an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis in an Open-Label Extension Study
10:54 AM - 11:06 AM Your local time